Hitting on the move: targeting intrinsically disordered protein states of the MDM2-p53 interaction

p53, the cellular gatekeeper for growth and division

Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693 · see citing works

Surfing the p53 network

Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607 · see citing works

p53, guardian of the genome

Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138 · see citing works

Gradient-tailored excitation for single-quantum NMR spectroscopy of aqueous solutions

Piotto, M., Saudek, V., & Sklenář, V. (1992) · Journal of Biomolecular NMR · doi:10.1007/bf02192855 · Cited by 3,720 · see citing works

Innovation in the pharmaceutical industry: New estimates of R&D costs

DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016) · Journal of Health Economics · doi:10.1016/j.jhealeco.2016.01.012 · Cited by 3,359 · see citing works

Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain

Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206 · see citing works

Discovering High-Affinity Ligands for Proteins: SAR by NMR

Shuker, S. B., Hajduk, P. J., Meadows, R. P., & Fesik, S. W. (1996) · Science · doi:10.1126/science.274.5292.1531 · Cited by 2,045 · see citing works

A Medicinal Chemist’s Guide to Molecular Interactions

Bissantz, C., Kuhn, B., & Ståhl, M. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100112j · Cited by 1,773 · see citing works

Using chemical shift perturbation to characterise ligand binding

Williamson, M. P. (2013) · Progress in Nuclear Magnetic Resonance Spectroscopy · doi:10.1016/j.pnmrs.2013.02.001 · Cited by 1,436 · see citing works

Principles and Applications of Halogen Bonding in Medicinal Chemistry and Chemical Biology

Wilcken, R., Zimmermann, M. O., Lange, A., Joerger, A. C., & Boeckler, F. M. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3012068 · Cited by 1,364 · see citing works

Structure-Based Design of Spiro-oxindoles as Potent, Specific Small-Molecule Inhibitors of the MDM2−p53 Interaction

Ding, K., Lu, Y., Nikolovska-Coleska, Z., Wang, G., Qiu, S., Shangary, S., Gao, W., Qin, D., Stuckey, J., Krajewski, K., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm051122a · Cited by 702 · see citing works

Mapping of the p53 and mdm-2 Interaction Domains

Chen, J., Maréchal, V., & Levine, A. J. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.7.4107 · Cited by 689 · see citing works

Improved Sensitivity of HSQC Spectra of Exchanging Protons at Short Interscan Delays Using a New Fast HSQC (FHSQC) Detection Scheme That Avoids Water Saturation

Mori, S., Abeygunawardana, C., Johnson, M., et al. (1995) · Journal of Magnetic Resonance Series B · doi:10.1006/jmrb.1995.1109 · Cited by 644 · see citing works

Intrinsically disordered proteins: a 10-year recap

Tompa, P. (2012) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2012.08.004 · Cited by 624 · see citing works

Functions of the MDM2 oncoprotein

Freedman, D. A., Wu, L., & Levine, A. J. (1999) · Cellular and Molecular Life Sciences · doi:10.1007/s000180050273 · Cited by 573 · see citing works

Unusual biophysics of intrinsically disordered proteins.

Uversky, V. (2013) · Biochimica et Biophysica Acta · doi:10.1016/j.bbapap.2012.12.008 · Cited by 536 · see citing works

A decade and a half of protein intrinsic disorder: Biology still waits for physics

Uversky, V. (2013) · Protein Science · doi:10.1002/pro.2261 · Cited by 478 · see citing works

NMR methods for the determination of protein–ligand dissociation constants

FIELDING, L. (2007) · Progress in Nuclear Magnetic Resonance Spectroscopy · doi:10.1016/j.pnmrs.2007.04.001 · Cited by 405 · see citing works

Local Structural Elements in the Mostly Unstructured Transcriptional Activation Domain of Human p53

Lee, H., Mok, K. H., Muhandiram, R., Park, K.-H., Suk, J.-E., Kim, D., Chang, J., Sung, Y. C., Choi, K. Y., & Han, K. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003107200 · Cited by 329 · see citing works

Chalcone Derivatives Antagonize Interactions between the Human Oncoprotein MDM2 and p53

Stoll, R., Renner, C., Hansen, S., Palme, S., Klein, C., Belling, A., Żesławski, W., Kamionka, M., Rehm, T., Mühlhahn, P., et al. (2000) · Biochemistry · doi:10.1021/bi000930v · Cited by 275 · see citing works

p21(WAF1) Mediates Cell-Cycle Inhibition, Relevant to Cancer Suppression and Therapy

El‐Deiry, W. S. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-2055 · Cited by 258 · see citing works

Mapping of the p53 and mdm-2 Interaction Domains

Chen, J., Maréchal, V., & Levine, A. J. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.7.4107-4114.1993 · Cited by 247 · see citing works

Immunochemical analysis of the interaction of p53 with MDM2;--fine mapping of the MDM2 binding site on p53 using synthetic peptides.

Picksley, S. M., Vojtĕsek, B., Sparks, A., & Lane, D. P. (1994) · PubMed · Cited by 238 · see citing works

Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery

Popowicz, G. M., Czarna, A., Wolf, S., Wang, K., Wang, W., Dömling, A. S. S., & Holak, T. A. (2010) · Cell Cycle · doi:10.4161/cc.9.6.10956 · Cited by 232 · see citing works

Cyclic Guanidine Organic Catalysts: What Is Magic About Triazabicyclodecene?

Kiesewetter, M. K., Scholten, M. D., Kirn, N., Weber, R. L., Hedrick, J. L., & Waymouth, R. M. (2009) · The Journal of Organic Chemistry · doi:10.1021/jo902369g · Cited by 213 · see citing works

Transient Pockets on Protein Surfaces Involved in Protein−Protein Interaction

Eyrisch, S., & Helms, V. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070095g · Cited by 212 · see citing works

Targeting the p53–MDM2 interaction to treat cancer

Klein, C., & Vassilev, L. T. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602164 · Cited by 204 · see citing works

Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain

Popowicz, G. M., Czarna, A., & Holak, T. A. (2008) · Cell Cycle · doi:10.4161/cc.6365 · Cited by 195 · see citing works

The way to NMR structures of proteins.

Wüthrich, K. (2001) · Nature Structural Biology · doi:10.1038/nsb1101-923 · Cited by 191 · see citing works

Targeting the Intrinsically Disordered Structural Ensemble of α-Synuclein by Small Molecules as a Potential Therapeutic Strategy for Parkinson’s Disease

Tóth, G., Gardai, S. J., Zago, W., Bertoncini, C. W., Cremades, N., Roy, S. L., Tambe, M. A., Rochet, J.-C., Galvagnion, C., Skibinski, G., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087133 · Cited by 151 · see citing works

Structure of Free MDM2 N-terminal Domain Reveals Conformational Adjustments that Accompany p53-binding

Uhrı́nová, S., Uhrı́n, D., Powers, H., Watt, K., Zheleva, D. I., Fischer, P. M., McInnes, C., & Barlow, P. N. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.05.010 · Cited by 141 · see citing works

Robust Generation of Lead Compounds for Protein–Protein Interactions by Computational and MCR Chemistry: p53/Hdm2 Antagonists

Czarna, A., Beck, B., Srivastava, S., Popowicz, G. M., Wolf, S., Huang, Y., Biśta, M., Holak, T. A., & Dömling, A. S. S. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.201001343 · Cited by 134 · see citing works

The α-helical FXXΦΦ motif in p53: TAF interaction and discrimination by MDM2

Uesugi, M., & Verdine, G. L. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.14801 · Cited by 133 · see citing works

Molecular Basis for the Inhibition of p53 by Mdmx

Popowicz, G. M., Czarna, A., Rothweiler, U., Szwagierczak, A., Krajewski, M., Weber, L., & Holak, T. A. (2007) · Cell Cycle · doi:10.4161/cc.6.19.4740 · Cited by 131 · see citing works

Small molecular weight protein–protein interaction antagonists—an insurmountable challenge?

Dömling, A. S. S. (2008) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2008.04.603 · Cited by 128 · see citing works

Structure-based Inhibitor Design for the Intrinsically Disordered Protein c-Myc

Chen, Y., Niu, X., Jin, F., Liu, Z., Jin, C., & Lai, L. (2016) · Scientific Reports · doi:10.1038/srep22298 · Cited by 115 · see citing works

Targeting Intrinsically Disordered Transcription Factors: Changing the Paradigm

Tsafou, K., Tiwari, P. B., Forman-Kay, J. D., Metallo, S. J., & Toretsky, J. A. (2018) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.04.008 · Cited by 110 · see citing works

Short and Diverse Route Toward Complex Natural Product-Like Macrocycles

Beck, B., Larbig, G., Mejat, B., et al. (2003) · Organic Letters · doi:10.1021/ol034077e · Cited by 109 · see citing works

NMR-Based Approaches for the Identification and Optimization of Inhibitors of Protein–Protein Interactions

Barile, E., & Pellecchia, M. (2014) · Chemical Reviews · doi:10.1021/cr500043b · Cited by 109 · see citing works

Enabling Large-Scale Design, Synthesis and Validation of Small Molecule Protein-Protein Antagonists

Koes, D. R., Khoury, K., Huang, Y., Wang, W., Biśta, M., Popowicz, G. M., Wolf, S., Holak, T. A., Dömling, A. S. S., & Camacho, C. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032839 · Cited by 104 · see citing works

How To Design a Successful p53–MDM2/X Interaction Inhibitor: A Thorough Overview Based on Crystal Structures

Estrada‐Ortiz, N., Neochoritis, C. G., & Dömling, A. S. S. (2015) · ChemMedChem · doi:10.1002/cmdc.201500487 · Cited by 100 · see citing works

High affinity interaction of the p53 peptide-analogue with human Mdm2 and Mdmx

Czarna, A., Popowicz, G. M., Pęcak, A., Wolf, S., Dubin, G., & Holak, T. A. (2009) · Cell Cycle · doi:10.4161/cc.8.8.8185 · Cited by 99 · see citing works

Targeting intrinsically disordered proteins in rational drug discovery

Ambadipudi, S., & Zweckstetter, M. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2016.1107041 · Cited by 97 · see citing works

Flexible lid to the p53-binding domain of human Mdm2: Implications for p53 regulation

McCoy, M. A., Gesell, J. J., Senior, M. M., & Wyss, D. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0334477100 · Cited by 95 · see citing works

Quantitative Lid Dynamics of MDM2 Reveals Differential Ligand Binding Modes of the p53-Binding Cleft

Showalter, S. A., Bruschweiler‐Li, L., Johnson, E., Zhang, F., & Brüschweiler, R. (2008) · Journal of the American Chemical Society · doi:10.1021/ja800201j · Cited by 91 · see citing works

Efficient Isocyanide-less Isocyanide-Based Multicomponent Reactions

Neochoritis, C. G., Stotani, S., Mishra, B. A., et al. (2015) · Organic Letters · doi:10.1021/acs.orglett.5b00759 · Cited by 73 · see citing works

The central valine concept provides an entry in a new class of non peptide inhibitors of the p53–MDM2 interaction

Furet, P., Chêne, P., Pover, A. D., Stachyra, T., Lisztwan, J. H., Kallen, J. A., & Masuya, K. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.03.083 · Cited by 73 · see citing works

Ordering of the N-Terminus of Human MDM2 by Small Molecule Inhibitors

Michelsen, K., Jordan, J. B., Lewis, J. K., Long, A. M., Yang, E., Rew, Y., Zhou, J., Yakowec, P. S., Schnier, P. D., Huang, X. Y., et al. (2012) · Journal of the American Chemical Society · doi:10.1021/ja305839b · Cited by 71 · see citing works

Exploiting Transient Protein States for the Design of Small-Molecule Stabilizers of Mutant p53

Joerger, A. C., Bauer, M. R., Wilcken, R., Baud, M. G. J., Harbrecht, H., Exner, T. E., Boeckler, F. M., Spencer, J., & Fersht, A. R. (2015) · Structure · doi:10.1016/j.str.2015.10.016 · Cited by 62 · see citing works

Transient Protein States in Designing Inhibitors of the MDM2-p53 Interaction

Biśta, M., Wolf, S., Khoury, K., Kowalska, K., Huang, Y., Wrona, E., Arciniega, M., Popowicz, G. M., Holak, T. A., & Dömling, A. S. S. (2013) · Structure · doi:10.1016/j.str.2013.09.006 · Cited by 56 · see citing works

Interrogation of MDM2 Phosphorylation in p53 Activation Using Native Chemical Ligation: The Functional Role of Ser17 Phosphorylation in MDM2 Reexamined

Zhan, C., Varney, K. M., Yuan, W., Zhao, L., & Lu, W. (2012) · Journal of the American Chemical Society · doi:10.1021/ja301255n · Cited by 49 · see citing works

2,3′-Bis(1′H-indole) heterocycles: New p53/MDM2/MDMX antagonists

Neochoritis, C. G., Wang, K., Estrada‐Ortiz, N., Herdtweck, E., Kubica, K., Twarda‐Clapa, A., Żak, K. M., Holak, T. A., & Dömling, A. S. S. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.11.019 · Cited by 46 · see citing works

A therapeutic patent overview of MDM2/X-targeted therapies (2014–2018)

Skalniak, Ł., Surmiak, E., & Holak, T. A. (2019) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2019.1582645 · Cited by 45 · see citing works

Discovery of Highly Potent p53-MDM2 Antagonists and Structural Basis for Anti-Acute Myeloid Leukemia Activities

Huang, Y., Wolf, S., Beck, B., Köhler, L.-M., Khoury, K., Popowicz, G. M., Goda, S. K., Subklewe, M. S., Twarda‐Clapa, A., Holak, T. A., et al. (2014) · ACS Chemical Biology · doi:10.1021/cb400728e · Cited by 42 · see citing works

Modulation of p53 binding to MDM2: computational studies reveal important roles of Tyr100

Dastidar, S. G., Lane, D. P., & Verma, C. S. (2009) · BMC Bioinformatics · doi:10.1186/1471-2105-10-s15-s6 · Cited by 40 · see citing works

Leuckart–Wallach Route Toward Isocyanides and Some Applications

Neochoritis, C. G., Zarganes‐Tzitzikas, T., Stotani, S., et al. (2015) · ACS Combinatorial Science · doi:10.1021/acscombsci.5b00066 · Cited by 38 · see citing works

A nchor Q uery: R apid online virtual screening for small‐molecule protein–protein interaction inhibitors

Koes, D. R., Dömling, A. S. S., & Camacho, C. J. (2017) · Protein Science · doi:10.1002/pro.3303 · Cited by 35 · see citing works

Rational design and synthesis of 1,5-disubstituted tetrazoles as potent inhibitors of the MDM2-p53 interaction

Surmiak, E., Neochoritis, C. G., Musielak, B., Twarda‐Clapa, A., Kurpiewska, K., Dubin, G., Camacho, C. J., Holak, T. A., & Dömling, A. S. S. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.11.029 · Cited by 34 · see citing works

Artificial Macrocycles as Potent p53–MDM2 Inhibitors

Estrada‐Ortiz, N., Neochoritis, C. G., Twarda‐Clapa, A., Musielak, B., Holak, T. A., & Dömling, A. S. S. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00219 · Cited by 32 · see citing works

1,4,5-Trisubstituted Imidazole-Based p53–MDM2/MDMX Antagonists with Aliphatic Linkers for Conjugation with Biological Carriers

Twarda‐Clapa, A., Krzanik, S., Kubica, K., Guzik, K., Łabuzek, B., Neochoritis, C. G., Khoury, K., Kowalska, K., Czub, M., Dubin, G., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00104 · Cited by 31 · see citing works

Scaffold hopping via ANCHOR.QUERY: β-lactams as potent p53-MDM2 antagonists

Shaabani, S., Neochoritis, C. G., Twarda‐Clapa, A., et al. (2017) · MedChemComm · doi:10.1039/c7md00058h · Cited by 25 · see citing works

p53–MDM2 and MDMX Antagonists

Neochoritis, C. G., Estrada‐Ortiz, N., Khoury, K., & Dömling, A. S. S. (2014) · Annual reports in medicinal chemistry · doi:10.1016/b978-0-12-800167-7.00012-2 · Cited by 16 · see citing works

A fluorinated indole‐based MDM 2 antagonist selectively inhibits the growth of p53wt osteosarcoma cells

Skalniak, Ł., Twarda‐Clapa, A., Neochoritis, C. G., Surmiak, E., Machula, M., Wiśniewska, A., Łabuzek, B., Ali, A. M., Krzanik, S., Dubin, G., et al. (2019) · FEBS Journal · doi:10.1111/febs.14774 · Cited by 16 · see citing works

Intrinsically Disordered Proteins as Drug Targets

Sánchez-Martínez, M. (2017) · MOJ Proteomics & Bioinformatics · doi:10.15406/mojpb.2017.05.00157 · Cited by 8 · see citing works

Hitting a Moving Target: Targeting Transient Protein States

Bauer, M. R., & Boeckler, F. M. (2013) · Structure · doi:10.1016/j.str.2013.11.003 · Cited by 6 · see citing works

The negative relativistic toda hierarchy and rational poisson brackets

da Costa, J. M. N., & Damianou, P. A. (2004) · Qualitative Theory of Dynamical Systems · doi:10.1007/bf02968133 · Cited by 1 · see citing works

Development of MDM2 degraders based on ligands derived from Ugi reactions: Lessons and discoveries

Wang, B., Liu, J., Tandon, I., Wu, S., Teng, P., Liao, J., & Tang, W. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113425 · Cited by 67 · see citing works

Mdmx as an essential regulator of p53 activity

Marine, J., & Jochemsen, A. G. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.03.151 · Cited by 186 · see citing works

Soft-Modes Guided Pharmacophore Modeling Succeeds in Identification of Potent MDM2 InhibitorsPreprint

Kantarci-Carsibasi, N., & Lokmaci, E. (2022) · doi:10.22541/au.164873327.72822666/v1

How To Design a Successful p53–MDM2/X Interaction Inhibitor: A Thorough Overview Based on Crystal Structures

Estrada‐Ortiz, N., Neochoritis, C. G., & Dömling, A. S. S. (2015) · ChemMedChem · doi:10.1002/cmdc.201500487 · Cited by 100 · see citing works

Small Molecule Inhibitors of the MDM2-p53 Interaction Discovered by Ensemble-Based Receptor Models

Bowman, A. L., Nikolovska‐Coleska, Z., Zhong, H. A., Wang, S., & Carlson, H. A. (2007) · Journal of the American Chemical Society · doi:10.1021/ja073687x · Cited by 127 · see citing works

Computational-based drug design of novel small molecules targeting p53-MDMX interaction

Egbemhenghe, A. U., Aderemi, O. E., Omotara, B. S., Akhimien, F. I., Osabuohien, F. O., Adedapo, H. A., Temionu, O. R., Egejuru, W. A., Ajala, C. F., Ihunanya, M. F., et al. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2245483 · Cited by 6 · see citing works